SFDA Experts Set To Determine Approval Of H1N1 Vaccine
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA scheduled final tests of an H1N1 flu vaccine that could mean immediate approval for release to the public. The vaccine has completed clinical trials, so the SFDA called in experts for a certification meeting with limited public and media opportunity to express concerns, but results could be determined by the end of the day. The agency is acting after a week that saw the number of H1N1 cases grew to near 3,398, although no deaths have been confirmed. (Click here for more
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
With a global supply chain and commercial platform, the Viatris entity to be formed by the merger of Mylan and Pfizer’s Upjohn unit wants to be the partner of choice for mid-sized products overlooked by companies focused on blockbusters.
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.